© 2018 

Group Profile

Our research focuses on polymeric materials, organic nanotechnologies and nanomedicine.

We aim to develop novel technologies that address real-world industrial challenges and unmet clinical needs. Through a mixture of fundamental studies and the application of new science the group creates new understanding, develops new materials and investigates  applications across a diverse range of scale-able end-uses. Our therapeutic studies specifically target improved drug delivery and dose optimisation for infectious diseases.

New materials chemistry developed in the group has led to start-up/spin-out companies, engagement with global charities and multi-national companies and human trials of the world's first nanomedicines for HIV therapy.

Our polymer synthesis techniques include: conventional free radical polymerisation, ambient anionic polymerisation, step-growth polymerisation, ring opening polyemrisation, controlled radical polymerisation (ATRP, RAFT), and various new branched vinyl copolymerisations. Materials introduced through our research include new complex polymer architectures (eg new dendrimers, branched copolymer emulsifiers, hyperbranched-polydendrons) and organic nanoparticle dispersions.

Our colloidal science includes novel emulsions, nanoprecipitations, organic nanoparticles and active/triggered particles. These are enabled by novel liquid manipulation/ processing, emulsion templated freeze drying, emulsion spray drying and the new materials developed during our synthetic activities. 

Selected recent publications

Long-acting injectable atovaquone nanomedicines for malaria prophylaxis.

R. P. Bakshi, L. Tatham, A. C. Savage, A. K. Tripathi, G. Mlambo, M. M. Ippolito, E. Nenortas, S. P. Rannard, A. Owen, T. A. Shapiro, Nature Commun., 2018, 9, 315

Controlling drug release from non-aqueous environments: moderating delivery from ocular silicone oil drug reservoirs to combat proliferative vitreoretinopathy

H. Cauldbeck, M. Le Hellaye, M. Long, S. M. Kennedy, R. L. Williams, V. R, Kearns and S. P. Rannard J. Control. Rel., 2016, 244, 41–51

Accelerated oral nanomedicine discovery from miniaturised screening to clinical production exemplified by paediatric HIV nanotherapies

M. Giardiello, N. J. Liptrott, T. O. McDonald, D. Moss, M. Siccardi, P. Martin, D. Smith, R. Gurjar, S. P. Rannard and A. Owen Nat. Commun. 2016, 7, 13184

This site was designed with the
website builder. Create your website today.
Start Now